Name: NLS PHARMACEUTICS LTD (NLSP) Stock
Brand: NLS PHARMACEUTICS LTD
Rating: 2 (3 reviews)

NLSP Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Chartmill - Mentions: BTU TGE AMTD FMFC ...

Stay updated with the stocks that are on the move in today's after-hours session.

3 days ago - By: Chartmill - Mentions: ATEC SPSC ARDX CRBP ...

Top movers in Thursday's after hours session

3 days ago - By: NLS Pharmaceutics Ltd.

NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs

4 days ago - By: NLS Pharmaceutics Ltd.

NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger

4 days ago - By: NLS Pharmaceutics Ltd.

NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem

4 days ago - By: NLS Pharmaceutics Ltd.

NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares

6 days ago - By: NLS Pharmaceutics Ltd.

NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies

10 days ago - By: Benzinga - Mentions: CNC MOH IBIO BIOA ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session

10 days ago - By: NLS Pharmaceutics Ltd.

NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025

a month ago - By: NLS Pharmaceutics Ltd.

NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting

2 months ago - By: NLS Pharmaceutics Ltd.

Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger

2 months ago - By: NLS Pharmaceutics Ltd.

NLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes Patients

4 months ago - By: NLS Pharmaceutics Ltd.

NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy

4 months ago - By: NLS Pharmaceutics AG

NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing

5 months ago - By: NLS Pharmaceutics Ltd.

NLS Pharmaceutics CEO Issues Letter to Shareholders

6 months ago - By: NLS Pharmaceutics Ltd.

NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting

7 months ago - By: Benzinga

What's Going On With NLS Pharmaceutics Shares Monday?

7 months ago - By: ACCESS Newswire

NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement

8 months ago - By: NLS Pharmaceutics Ltd.

NLS Pharmaceutics CEO Issues Letter to Shareholders

8 months ago - By: NLS Pharmaceutics Ltd.

NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform

8 months ago - By: NLS Pharmaceutics Ltd.

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment

9 months ago - By: Kadimastem ltd.

NLS PHARMACEUTICS LTD (NLSP) Stock News

NLSP Latest News, Press Relases and Analysis

Stay updated with the stocks that are on the move in today's after-hours session.

Top movers in Thursday's after hours session

NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs

NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger

NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem

NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares

NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies

12 Health Care Stocks Moving In Thursday's Pre-Market Session

NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025

NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting

Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger

NLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes Patients

NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy

NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing

NLS Pharmaceutics CEO Issues Letter to Shareholders

NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting

What's Going On With NLS Pharmaceutics Shares Monday?

NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement

NLS Pharmaceutics CEO Issues Letter to Shareholders

NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies